[Results of clinical trials with the gluconeogenesis inhibitor 2-(3-methylcinnamylhydrazono)-propionate (MCHP)].
Many compounds which directly or indirectly inhibit gluconeogenesis have been described. Some of them showed hypoglycemic action in animal experiments. 2-(3-Methylcinnamylhydrazono)-Propionat (MCHP) a derivative of hydrazine demonstrated marked hypoglycemic action in animal experiments. Nontheless the administration of MCHP to type II diabetic patients showed no hypoglycemic action. Clinical or biochemical sideeffects could not be observed.
Paschke
R
R
II. Medizinische Klinik, Klinkum Mannheim der Universität Heidelberg, Mannheim.
Schwedes
U
U
Kühnle
H
H
Peter
J
J
Schmeidl
R
R
Usadel
K H
KH
D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism; D002934:Cinnamates / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects*; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D011897:Random Allocation
D001786:Blood Glucose; D002934:Cinnamates; D007004:Hypoglycemic Agents; C039804:BM 42304; D005905:Glyburide
Ergebnisse der klinischen Prüfung des Glukoneogenesehemmers 2-(3-Methylcinnamylhydrazono)-Propionat (MCHP).